Press Release Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 7 hours ago
Press Release Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer Jul 27
Press Release Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Jul 14
Press Release Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties Jul 14